U.S. Food and Drug Administration Approves CSL's ANDEMBRY ® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patie

CSL has received FDA approval for ANDEMBRY, a once-monthly subcutaneous treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. Clinical trial data demonstrated a median reduction of over 99% in HAE attacks compared to placebo, with 62% of patients remaining attack-free during the treatment period. ANDEMBRY, CSL's first homegrown monoclonal antibody, uniquely inhibits factor XIIa and will be commercially available before the end of June, expanding CSL’s HAE franchise.

Analysis

CSL has secured U.S. Food and Drug Administration (FDA) approval for ANDEMBRY (garadacimab-gxii), a novel, once-monthly subcutaneous treatment for preventing attacks in patients aged 12 years and older with hereditary angioedema (HAE). This approval marks a significant achievement for CSL, as ANDEMBRY is its first internally discovered and developed monoclonal antibody. The drug targets factor XIIa, inhibiting the HAE cascade at its initiation point, a distinct mechanism compared to other HAE therapies. Efficacy data from the pivotal Phase 3 VANGUARD trial was compelling: ANDEMBRY demonstrated a median reduction in HAE attacks of over 99% and a least squares mean reduction of 89.2% compared to placebo. Furthermore, 62% of patients treated with ANDEMBRY remained attack-free throughout the treatment period, and there were similar high median reductions in attacks requiring on-demand therapy (over 99%) and moderate or severe attacks (over 99%). CSL intends to launch ANDEMBRY commercially immediately, with availability anticipated before the end of June, which will expand its HAE franchise. The most common adverse reactions observed in the pivotal trial were nasopharyngitis and abdominal pain.

Key Decisions for Investors

• The FDA approval of ANDEMBRY, supported by robust efficacy data including a median HAE attack reduction exceeding 99% and a high proportion of attack-free patients, presents a compelling growth opportunity for CSL within its HAE franchise.
• Investors should monitor the commercial launch execution and initial market uptake of ANDEMBRY, as its convenient once-monthly dosing regimen and novel mechanism of action could drive significant adoption and revenue generation.
• The successful development and approval of ANDEMBRY as CSL's first homegrown monoclonal antibody may enhance the company's R&D profile and signal potential for future value creation from its internal pipeline, warranting consideration in valuation models.